Strides Pharma Science Limited has informed the Exchange regarding a press release dated May 22, 2025, titled "Strides Delivers strong FY25 Results, Exceeding Outlook Across All Metrics. ".
STAR · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 5.7 pts more than Nifty Microcap 250 and 5.7 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Strides Pharma Science reported FY25 revenue of ₹45,653m, up 17.2% YoY, beating its own guidance of 12-15% growth. EBITDA grew 36.8% to ₹8,028m with margins expanding 252bps to 17.6%, also above the guided range of ₹7,500-8,000m. US business revenue rose 21.8% to $291m, with 7 new product launches in FY25 and a total of 73 commercialized products. Operational PAT surged 12x to ₹3,447m, and the company reduced net debt by ₹5,128m, bringing Net Debt-to-EBITDA to 1.9x. The Board has recommended a dividend of ₹4 per share, and management reiterated the target of ~$400m US revenue by FY27-28.
This is a positive beat across revenue, margins, profitability, and debt reduction, which should support investor confidence. The dividend announcement and reaffirmed US growth target add to the positive sentiment, though the stock reaction will depend on how much of this was already priced in.